Tumor News and Research

RSS

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.

29 May 2015

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer.

29 May 2015

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

ESSA Pharma Inc. today reported financial results for the second quarter and three and six months ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with International Financial Reporting Standards.

29 May 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

A new collaborative study led by researchers at Sanford-Burnham Medical Research Institute, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors.

28 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the most common and deadly form of brain tumor. In findings published May 27 in Science Translational Medicine, the researchers suggest that a transporter known as SXC is responsible for boosting levels of glutamate in the brains of some glioma patients.

28 May 2015

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting.

28 May 2015

EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

EKF subsidiary, Selah Genomics’ newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141...

From EKF Diagnostics 28 May 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015.

28 May 2015

Progression of different types of breast cancer influenced differently by tumor microenvironment

Our environment can have a major impact on how we develop, and it turns out it's no different for cancer cells. In work published today in Neoplasia, a team of researchers led by Associate Professor Mikala Egeblad at Cold Spring Harbor Laboratory found that two different mouse models of breast cancer progressed differently based on characteristics of the tumor microenvironment - the area of tissue in which the tumor is embedded.

28 May 2015

AACR, Bayer partner to expand Basic Cancer Research Fellowship Program for 2015

The American Association for Cancer Research and Bayer HealthCare are pleased to announce a new partnership that will expand AACR's Basic Cancer Research Fellowship Program for 2015.

28 May 2015

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System are the first in the United States to treat osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, using an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method.

28 May 2015

Strand Life Sciences to launch expanded StrandAdvantage pan-cancer genomic profiling service at ASCO 2015

Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced it will introduce its expanded StrandAdvantage pan-cancer genomic profiling service later this month at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

27 May 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago.

27 May 2015

Understanding the antimicrobial action of borrelidin: an interview with Dr Min Guo, TSRI

Borrelidin is a naturally occurring antibiotic isolated from the Streptomyces species and initially from Streptomyces rochei in 1949. It is called Borrelidin because it was firstly discovered as having anti-Borrelia activity. Borrelia is a type of bacteria...

27 May 2015

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Guardant Health today announced that five abstracts submitted by the University of California, San Francisco; University of California, San Diego; and MD Anderson highlighting the performance and clinical utility of Guardant360 have been accepted for oral and poster presentations at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29-June 2.

27 May 2015

Tiny drug-delivery system can help identify brain tumor types through 'virtual biopsies'

Biomedical researchers at Cedars-Sinai have invented a tiny drug-delivery system that can identify cancer cell types in the brain through "virtual biopsies" and then attack the molecular structure of the disease.

27 May 2015

NYU chemists find that microRNA can serve as 'decoder ring' for understanding biological functions

MicroRNA can serve as a "decoder ring" for understanding complex biological processes, a team of New York University chemists has found. Their study, which appears in Proceedings of the National Academy of Sciences, points to a new method for decrypting the biological functions of enzymes and identifying those that drive diseases.

27 May 2015

Alternative generic strategy for breast cancer treatment

Maxing out the inherently stressed nature of treatment-resistant breast cancer cells thwarts their adaptive ability to evolve genetic workarounds to treatment, a new study suggests.

27 May 2015

Tumor News and Research

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

Green tea components may help prevent prostate cancer development in at-risk men

ESSA Pharma reports net loss of $5.9 million for second quarter 2015

Researchers suggest new target for treating BRAF inhibitor-resistant melanoma tumors

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Data supporting anti-cancer potential of Biscayne’s GHRH antagonist to be discussed at ASCO Annual Meeting

EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Progression of different types of breast cancer influenced differently by tumor microenvironment

AACR, Bayer partner to expand Basic Cancer Research Fellowship Program for 2015

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Strand Life Sciences to launch expanded StrandAdvantage pan-cancer genomic profiling service at ASCO 2015

Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015

Understanding the antimicrobial action of borrelidin: an interview with Dr Min Guo, TSRI

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Tiny drug-delivery system can help identify brain tumor types through 'virtual biopsies'

NYU chemists find that microRNA can serve as 'decoder ring' for understanding biological functions

Alternative generic strategy for breast cancer treatment

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News